ANIMATION

Voxelotor An Investigational Drug for Sickle Cell Disease

Share this animation:

In collaboration with Global Blood Therapeutics, our folks here at XVIVO created this medical animation to illustrate the mechanism of action of a potential drug candidate for the treatment of sickle cell disease (SCD). SCD is caused by a point mutation in the hemoglobin gene, resulting in the aggregation and polymerization of deoxygenated hemoglobin. This causes structural deformation of red blood cells into the characteristic “sickle” shape, which can lead to cellular lysis and vaso-occlusion, impairing oxygen delivery and causing a number of health effects. Voxelotor is an investigational disease-modifying drug that binds to hemoglobin and increases its affinity to oxygen, keeping it in its oxygenated state. By diluting the concentration of deoxygenated hemoglobin, mutant hemoglobin may be kept from polymerizing, thus preventing cellular sickling and its many clinical consequences.

Share It:
Contact XVIVO

Client


Voxelotor An Investigational Drug for Sickle Cell Disease

Both the quality of the final product and my experience working with XVIVO has reinforced my interest in a long-term collaboration with this team.

Alain Viel PhD, Senior Lecturer and Director of Undergraduate Research in Molecular and Cellular Biology, Harvard University
Share this animation: